[go: up one dir, main page]

AU2001277723A1 - Ppardelta activators - Google Patents

Ppardelta activators

Info

Publication number
AU2001277723A1
AU2001277723A1 AU2001277723A AU7772301A AU2001277723A1 AU 2001277723 A1 AU2001277723 A1 AU 2001277723A1 AU 2001277723 A AU2001277723 A AU 2001277723A AU 7772301 A AU7772301 A AU 7772301A AU 2001277723 A1 AU2001277723 A1 AU 2001277723A1
Authority
AU
Australia
Prior art keywords
alkyl
oxygen
free valency
sulfur
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001277723A
Inventor
Tsuyoshi Endo
Takashi Kanda
Kunio Kobayashi
Seiichiro Masui
Nobutaka Mochiduki
Shogo Sakuma
Toshihiro Takahashi
Atsushi Tendo
Tomio Yamakawa
Shinichi Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Chemiphar Co Ltd
Original Assignee
Nippon Chemiphar Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co Ltd filed Critical Nippon Chemiphar Co Ltd
Publication of AU2001277723A1 publication Critical patent/AU2001277723A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds of the general formula (I) or salts thereof and activators of PPAR delta (peroxisome proliferator activated receptor delta ) containing the compounds or the salts as the active ingredient: wherein R<1> and R<2> each are hydrogen, C1-8 alkyl, an aryl or heterocyclic group which may be substituted, or the like; A is oxygen, sulfur, or the like; X<1> and X<2> are each a free valency, oxygen, S(O)p (wherein p is an integer of 0 to 2), C(=O), C(=O)NH, NHC(=O), CH=CH, or the like; Y is optionally substituted C1-8 alkylene; Z is oxygen or sulfur; R<3> and R<4> are each optionally substituted C1-8 alkyl; and R<8> is hydrogen or C1-8 alkyl, with the proviso that when X<1> is a free valency, X<2> is not O or S(O)p, while when X<1> is C(=O)NH, X<2> is not a free valency. <CHEM>
AU2001277723A 2000-08-11 2001-08-09 Ppardelta activators Abandoned AU2001277723A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000-243596 2000-08-11
JP2000243596 2000-08-11
JP2000402893 2000-12-28
JP2000-402893 2000-12-28
PCT/JP2001/006836 WO2002014291A1 (en) 2000-08-11 2001-08-09 PPARδ ACTIVATORS

Publications (1)

Publication Number Publication Date
AU2001277723A1 true AU2001277723A1 (en) 2002-02-25

Family

ID=26597787

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001277723A Abandoned AU2001277723A1 (en) 2000-08-11 2001-08-09 Ppardelta activators

Country Status (6)

Country Link
US (1) US6787552B2 (en)
EP (1) EP1310494B1 (en)
JP (1) JP4790969B2 (en)
AT (1) ATE542805T1 (en)
AU (1) AU2001277723A1 (en)
WO (1) WO2002014291A1 (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
GB0031109D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
WO2002070011A2 (en) * 2001-02-02 2002-09-12 Smithkline Beecham Corporation Treatment of ppar mediated diseases
RU2341513C2 (en) 2001-06-12 2008-12-20 Веллстат Терапьютикс Корпорейшн Compounds for treatment of metabolic diseases
BRPI0211844B8 (en) * 2001-08-10 2021-05-25 Nippon Chemiphar Co compound of phenoxy-acetic acid or one of its pharmaceutically acceptable salts, and, pharmaceutical composition
AU2002336532C1 (en) 2001-09-14 2008-10-16 Amgen, Inc Linked biaryl compounds
EP1480640B1 (en) * 2002-02-25 2007-08-15 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
KR100474202B1 (en) * 2002-05-04 2005-03-08 강헌중 Process for preparing thiazol derivative and the intermediate compounds for preparing the same
GB0214139D0 (en) * 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
US7220880B2 (en) 2002-06-19 2007-05-22 Eli Lilly And Company Amide linker peroxisome proliferator activated receptor modulators
DE10229777A1 (en) * 2002-07-03 2004-01-29 Bayer Ag Indoline-phenylsulfonamide derivatives
RU2005109555A (en) 2002-09-05 2005-11-10 Ново Нордиск А/С (DK) NEW VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR THERAPEUTIC APPLICATION
AU2003261935A1 (en) * 2002-09-06 2004-03-29 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
DE60332860D1 (en) 2002-10-28 2010-07-15 High Point Pharmaceuticals Llc NEW COMPOUNDS SUITABLE FOR THE TREATMENT OF PPARIALLY DISTRIBUTED DISEASES
PL376718A1 (en) 2002-10-28 2006-01-09 Novo Nordisk A/S Novel compounds, their preparation and use
US7129268B2 (en) 2002-10-28 2006-10-31 Novo Nordisk A/S Peroxisome proliferator activated receptor-active arylene acetic acid derivatives
US20050080115A1 (en) 2002-10-28 2005-04-14 Lone Jeppesen Novel compounds, their preparation and use
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
WO2004071509A1 (en) * 2003-02-12 2004-08-26 Nippon Chemiphar Co., Ltd. Oligodendrocyte differentiation promoters
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
DE10337839A1 (en) * 2003-08-18 2005-03-17 Bayer Healthcare Ag Indoline derivatives
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
ATE362367T1 (en) 2003-10-31 2007-06-15 Janssen Pharmaceutica Nv PHENOXYACETIC ACID DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) DUAL AGONISTS
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
WO2005105726A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
KR100907354B1 (en) * 2004-05-18 2009-07-10 쉐링 코포레이션 Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors
PE20060315A1 (en) * 2004-05-24 2006-05-15 Irm Llc THIAZOLE COMPOUNDS AS PPAR MODULATORS
US7833513B2 (en) * 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2006090920A1 (en) * 2005-02-28 2006-08-31 Nippon Chemiphar Co., Ltd. ACTIVATOR FOR PEROXISOME PROLIFERATOR ACTIVATING RECEPTOR δ
WO2006126714A1 (en) * 2005-05-25 2006-11-30 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-activated receptor
ATE529404T1 (en) 2005-06-30 2011-11-15 High Point Pharmaceuticals Llc PHENOXYACETIC ACIDS AS PPAR-DELTA ACTIVATORS
RU2008108221A (en) * 2005-09-07 2009-10-20 Плекссикон, Инк. (Us) COMPOUNDS ACTIVE AGAINST PPAR (RECEPTORS OF ACTIVATORS OF PROLIFERATION BY PEROXISIS)
JP5054028B2 (en) 2005-12-22 2012-10-24 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー New compounds, their manufacture and use
JP2009529512A (en) 2006-03-09 2009-08-20 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー Novel compounds, methods for their production and use
CN101466687B (en) * 2006-04-18 2012-04-11 日本化学医药株式会社 Activator of peroxisome proliferator activated receptor delta
WO2008035359A2 (en) * 2006-06-12 2008-03-27 Cadila Healthcare Limited Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
US20080004281A1 (en) * 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
TWI315304B (en) * 2006-08-31 2009-10-01 Univ Taipei Medical Indoline-sulfonamides compounds
WO2008030595A2 (en) 2006-09-08 2008-03-13 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced liver disease
EP2061442B1 (en) 2006-09-08 2016-08-31 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
WO2008051406A2 (en) 2006-10-20 2008-05-02 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
AU2007309568A1 (en) 2006-10-20 2008-05-02 Merck Sharp & Dohme Corp. Substituted imidazoles as bombesin receptor subtype-3 modulators
JP2010506917A (en) 2006-10-20 2010-03-04 メルク エンド カムパニー インコーポレーテッド Substituted imidazoles as bombesin receptor subtype 3 modulators
FR2910893A1 (en) * 2006-12-29 2008-07-04 Genfit Sa New Phenylthiazolyl/phenyloxazolyl derivatives are peroxisome proliferator-activated receptor agonist useful to treat e.g. diabetic, dyslipidemia, cardiovascular disease, hypertension, inflammatory diseases and cerebral ischaemia
NZ588612A (en) 2008-04-15 2012-08-31 Nippon Chemiphar Co Benzothiophen derivatives as activators of peroxisome proliferator activated receptor (PPAR)
ES2712052T3 (en) 2008-10-17 2019-05-09 Cymabay Therapeutics Inc Methods to reduce small and dense LDL particles
CN102264228A (en) 2008-10-22 2011-11-30 默沙东公司 New cyclic benzimidazole derivatives for antidiabetics
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2380884B1 (en) * 2008-12-01 2014-02-12 Mitsubishi Tanabe Pharma Corporation Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof
AU2010282399A1 (en) * 2009-08-14 2012-03-01 Cerenis Therapeutics Holding S.A. Use of PPAR delta ligands for the treatment or prevention of inflammation or energy metabolism/production related diseases
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
UA113053C2 (en) * 2010-12-28 2016-12-12 HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2013147118A1 (en) * 2012-03-29 2013-10-03 塩野義製薬株式会社 N-phenyl-n'-phenylsulfonylpiperazine derivative and method for producing intermediate for same
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX2015001500A (en) 2012-08-02 2015-04-08 Merck Sharp & Dohme Antidiabetic tricyclic compounds.
KR20150118158A (en) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 Antidiabetic bicyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CN105764916B (en) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 Ultrapure agonists of guanylate cyclase C, methods of making and using the same
TW201506024A (en) 2013-07-02 2015-02-16 必治妥美雅史谷比公司 Tricyclic carboxamide derivatives as potent ROCK inhibitors
JP6522602B2 (en) 2013-07-02 2019-05-29 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Tricyclic pyrido-carboxamide derivatives as ROCK inhibitors
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2959208C (en) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
CN109952292A (en) 2016-10-14 2019-06-28 Tes制药有限责任公司 Inhibitors of α-amino-β-carboxyhexadienedioic acid semialdehyde decarboxylase
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
AU2019216351B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
EP3746059A1 (en) 2018-01-31 2020-12-09 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of gastrointestinal stromal tumors
AR117122A1 (en) 2018-11-20 2021-07-14 Tes Pharma S R L A-AMINO-b-CARBOXIMUCONIC ACID INHIBITORS SEMIALDEHYDE DECARBOXYLASE
RU2714672C1 (en) * 2019-02-04 2020-02-19 Федеральное государственное автономное образовательное учреждение высшего образования "Санкт-Петербургский государственный университет аэрокосмического приборостроения" Device for determination of target movement parameters
CN114615982A (en) 2019-08-12 2022-06-10 德西费拉制药有限责任公司 Ripoctinib for treating gastrointestinal stromal tumor
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
SMT202400484T1 (en) 2019-12-30 2025-01-14 Deciphera Pharmaceuticals Llc COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREA
LT4084778T (en) 2019-12-30 2024-01-25 Deciphera Pharmaceuticals, Llc AMORPHOUS KINASE INHIBITOR PHARMACEUTICAL FORM AND METHODS OF THEIR USE
WO2022189856A1 (en) * 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2320387A1 (en) * 1973-04-21 1974-10-31 Boehringer Mannheim Gmbh PHENOXYALKYLCARBONIC ACID DERIVATIVES AND METHOD FOR PREPARING THE SAME
US5262540A (en) * 1989-12-20 1993-11-16 Bristol-Myers Squibb Company [2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters
GB9027023D0 (en) * 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
CA2090283A1 (en) * 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
JP2002503202A (en) 1996-02-02 2002-01-29 メルク エンド カンパニー インコーポレーテッド Antidiabetic drugs
DE69840510D1 (en) 1997-07-24 2009-03-12 Astellas Pharma Inc MEDICAL COMPOSITIONS WITH CHOLESTEROL EFFLUENT EFFECT
AU3275999A (en) * 1998-03-10 1999-09-27 Ono Pharmaceutical Co. Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
CN1148361C (en) * 1998-05-11 2004-05-05 武田药品工业株式会社 Oxyiminoalkanoic acid derivatives
US6589969B1 (en) * 1998-10-16 2003-07-08 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE60005973T2 (en) 1999-08-27 2004-05-13 Eli Lilly And Co., Indianapolis BIARYL-OXA (THIA) ZOL DERIVATIVES AND THEIR USE AS PPARS MODULATORS
PE20011010A1 (en) 1999-12-02 2001-10-18 Glaxo Group Ltd OXAZOLES AND THIAZOLES REPLACED AS AGONIST OF THE RECEPTOR ACTIVATED BY THE HUMAN PEROXISOMAS PROLIFERATOR

Also Published As

Publication number Publication date
WO2002014291A1 (en) 2002-02-21
EP1310494A1 (en) 2003-05-14
US6787552B2 (en) 2004-09-07
EP1310494B1 (en) 2012-01-25
JP4790969B2 (en) 2011-10-12
US20040097739A1 (en) 2004-05-20
EP1310494A4 (en) 2004-10-20
ATE542805T1 (en) 2012-02-15

Similar Documents

Publication Publication Date Title
AU2001277723A1 (en) Ppardelta activators
WO2003016291A1 (en) ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR δ
IL113313A (en) Heterocyclic compounds and pharmaceutical compositions containing the same
IL161351A0 (en) ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR delta
ID17851A (en) HETEROSICLIC COMPOUNDS, PRODUCTION AND USAGE
CA2247443A1 (en) Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to ppar-gamma
DK1447400T3 (en) Bicyclic compound
DK0695755T3 (en) pyrrolocarbazoles
WO2000044722A8 (en) Chondrongenesis promotors and indolin-2-one derivatives
GB9901691D0 (en) Chemical compounds
FI102348B1 (en) Improvements to stabilized isothiazolinone formulations
EP1197211A4 (en) Preventive and therapeutic agents for cancer
ES2024332A6 (en) New sulfonamides as antifungal agents.